JERSEY CITY, N.J., Jan. 11, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovativeanti-infective therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will participate in a panel entitled "Novel Ways to Treat and/or Address Infections" at the Cantor Antibiotics Summit at the Omni
About SCYNEXISSCYNEXIS, Inc. (NASDAQ:SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas. The Company's lead product candidate, SCY-078, is a novel IV/oral antifungal agent in Phase 2 clinical and pre-clinical development for the treatment of several serious and life-threatening invasive fungal infections caused by Candida and Aspergillus species. For more information, visit www.scynexis.com.
Investor RelationsSusan KimArgot PartnersTel: email@example.com
Media RelationsCammy DuongMacDougall Biomedical CommunicationsTel: firstname.lastname@example.org
View original content:http://www.prnewswire.com/news-releases/scynexis-to-participate-in-the-cantor-antibiotics-summit-300581688.html
SOURCE SCYNEXIS, Inc.
Subscribe to our Free Newsletters!
Fallopian tube cancer is a form of gynecologic cancer arising in the fallopian tubes, which are ...
Cushing syndrome is a collection of symptoms caused due to excessive amount of cortisol in the body ...
CAR T-cell therapy is a type of gene therapy where the patient's T-lymphocytes are genetically ...View All